Recommendations for Parkinson’s clinical trials using digital health technologies

Kimberly Ward Barowicz, BS, CAPM, SHRM-CP\(^1\), Marjan Meinders, PhD\(^2\), Mark Frasier, PhD\(^3\), Johan Hellsten, PhD\(^4\), Tairmae Kangarloo, BS\(^5\), Matthew Sullivan, PhD\(^6\), Cindy Zadikoff, MD\(^7\), Martijn Müller\(^8\), PhD, Diane Stephenson\(^9\), PhD

---

**Critical Path for Parkinson’s consortium’s Digital Drug Development Tool (3DT) initiative is a global pre-competitive collaboration to advance digital health technologies (DHT) in Parkinson’s.**

**3DT led a task force and produced recommendations and considerations for integrating digital health technologies in Parkinson’s clinical studies, prioritizing a participant-centered perspective.**

**The work of this collaboration places people with Parkinson’s at the center of study design, emphasizing their involvement and needs in the development and implementation of digital health technologies.**

---

**Incorporating the lived of experience is key to expediting the approval of much-needed treatments for individuals with Parkinson’s**

- **Unveiling insights**
  - Unique challenges arise with the inclusion of DHT (smart phones, sensors, etc.), requiring a comprehensive understanding of participant experiences

- **The time is now**
  - Digital technologies are increasingly integrated into Parkinson's clinical trials and there is a sense of urgency to adapt to this emerging need

- **Maximize efficiency**
  - Optimized studies can accelerate the path and minimize resource-intensive delays

---

**Task Force Outcome**

Recommendations in 3 key areas:

- Protocol Design
- Recruitment & Enrollment
- Protocol Compliance & Participant Retention

---

When using digital health technologies for assessing motor fluctuations or fatigue in Parkinson's, consider tailoring assessments, minimizing burden, and accounting for daily life impact, study duration, frequency of assessments, cultural/socio-economic factors, and the overall lived experience.